School of Medicine
Showing 21-30 of 341 Results
-
Dany Lamothe, MD
Clinical Assistant Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry
BioDr. Dany Lamothe is a board-certified, fellowship-trained psychiatrist with Stanford Health Care Gastrointestinal Behavioral Medicine. He is also a clinical assistant professor in the Department of Psychiatry and Behavioral Sciences, Division of Medical Psychiatry at Stanford University School of Medicine. He is the lead psychiatrist in the Gastrointestinal Behavioral Medicine Program and the medical director of psychiatric emergency services at Stanford Health Care. In addition, Dr. Lamothe is a supervisor of the Outpatient Psychiatry Clinic.
Dr. Lamothe specializes in addressing emotional, behavioral, and psychological factors that contribute to persistent gastrointestinal symptoms. He uses evidence-based therapies and medication management to help improve his patients’ quality of life.
Dr. Lamothe’s research interests include health anxiety, nutritional support outcomes in patients with gastroparesis, and integrative care models for disorders of gut-brain interaction.
Dr. Lamothe has published his research in peer-reviewed journals such as the Journal of the Academy of Consultation-Liaison Psychiatry, the Canadian Journal of Bioethics, and General Thoracic and Cardiovascular Surgery. He has also presented his research at international, national, and regional meetings, including the annual meetings of the Academy of Consultation-Liaison Psychiatry (ACLP), the American Psychiatric Association (APA), the Association for the Advancement of Philosophy and Psychiatry (AAPP), and the European Association of Psychosomatic Medicine (EAPM).
Dr. Lamothe is a member of the American Academy of Psychodynamic Psychiatry and Psychoanalysis, the ACLP, the APA, the Canadian Psychiatric Association, the EAPM, the International Experiential Dynamic Therapy Association (IEDTA), and the Society for Biopsychosocial Science and Medicine (SBSM). -
Lukas D. Landegger
Clinical Instructor, Otolaryngology (Head and Neck Surgery)
BioDr. Landegger is a clinician-scientist (otolaryngologist-head and neck surgeon) and Instructor at Stanford University School of Medicine. After gaining clinical as well as research experience in various countries (US, UK, France, Spain, Germany, Singapore, Australia), he specialized in otology with translational hearing research in Vienna, Austria and for five years in Boston (Mass Eye and Ear, Harvard Medical School), leading to a PhD in Neuroscience. Apart from clinical projects, current basic research foci are funded by a grant obtained from the American Society of Gene & Cell Therapy and include inner ear gene therapy, vestibular schwannoma, noise-induced hearing loss, and others.
-
Alfred Lane
Professor of Dermatology and of Pediatrics at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsDeveloping gene therapy for genetic skin diseases is my major focus. Prior to that, we are developing methods to give effective and efficient care to infants with rare and disabling genetic skin diseases including epidermolysis bullosa and ichthyosis as well as infants and children with unusual and difficult to manage vascular malformations. I am also interested in clinical studies within the NICU protecting premature infants skin and clinical studies in children with common skin diseases.
-
Barton Lane
Professor of Radiology (Diagnostic Radiology) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsAs a professor in the Medical Center Line, my primary investigative interest has been in clinical neuroradiology. This encompasses spinal cord and spine disease, degenerative and demyelinating diseases of the central nervous system, strokes and infarction, and chronic epilepsy syndromes. Facial and head and neck vascular malformations and hemangiomas have been a focus of interest for many years, with collaborative projects involving dermatology and functional restoration services.
-
Curtis Langlotz
Senior Associate Vice Provost for Research, Professor of Radiology (Integrative Biomedical Imaging Informatics), of Medicine (BMIR), of Biomedical Data Science and Senior Fellow at the Stanford Institute for Human-Centered AI
Current Research and Scholarly InterestsMy laboratory develops machine learning methods to help physicians detect disease and eliminate diagnostic errors. My laboratory is developing neural network systems that detect and classify disease on medical images. We also develop natural language processing methods that use the narrative radiology report for contrastive learning and other multi-modal methods that improve the accuracy and capability of machine learning systems.
-
Marvin Langston
Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work.
